For the second quarter of the fiscal year ending March 2027, consolidated results were: net sales 35,562.6 million yen, operating income 2,740 million yen, ordinary income 2,862 million yen, and interim net income attributable to owners of parent 2,006 million yen. Year-over-year, sales increased by 1.1%, operating income by 3.5%, and ordinary income by 8.5%, while interim net income decreased by -9.6%. Net assets rose to 80,225 million yen, and the equity ratio increased by 3.0 percentage points to 65.69%. No changes to the full-year forecast. Dividends are planned as total 65 yen for the year (32 yen at the second quarter-end, 33 yen at the third quarter-end).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4886","jir_company_name":"ASKA Pharmaceutical Holdings Co.,Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-04","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4886-20261104-02.pdf","jir_short_summary":"For the second quarter of the fiscal year ending March 2027, consolidated results were: net sales 35,562.6 million yen, operating income 2,740 million yen, ordinary income 2,862 million yen, and interim net income attributable to owners of parent 2,006 million yen. Year-over-year, sales increased by 1.1%, operating income by 3.5%, and ordinary income by 8.5%, while interim net income decreased by -9.6%. Net assets rose to 80,225 million yen, and the equity ratio increased by 3.0 percentage points to 65.69%. No changes to the full-year forecast. Dividends are planned as total 65 yen for the year (32 yen at the second quarter-end, 33 yen at the third quarter-end).","jir_summary":"### Overview of Performance\nThis period's results expanded with net sales of 35,626 million yen (YoY +1.1%), operating income of 2,740 million yen (YoY +3.5%), and ordinary income of 2,862 million yen (YoY +8.5%). Interim net income was 2,006 million yen (YoY -9.6%). By segment, Pharmaceuticals, Animal Health, and Overseas operations contributed to performance. Net assets amounted to 80,225 million yen, raising the equity ratio to 65.69%. Cash decreased but the financial structure remains stable. Research and development expenditures continue. Financial position shows total assets of 111,882 million yen and liabilities of 31,656 million yen.\n\n### Outlook and Key Notes\nThere is no change to the consolidated forecasts for the fiscal year ending March 2027. An earnings briefing will be held for institutional investors and analysts. Dividend policy for the fiscal year assumes 27 yen at the end of the first quarter, 32 yen at the end of the second quarter, and 33 yen at the end of the third quarter, totaling 65 yen for the year. Major segments focus on internal medicine, obstetrics & gynecology, and urology. The Company will continue to monitor the effects of drug price revisions and rising raw material costs. Multiple clinical development programs including AKP-022 are in progress.","jir_financial_highlights":"Net sales: 35,626 (YoY +1.1%)\nOperating income: 2,740 (YoY +3.5%)\nOrdinary income: 2,862 (YoY +8.5%)\nInterim net income attributable to owners of parent: 2,006 (YoY -9.6%)\nEquity ratio: 65.69% (YoY +3.0 percentage points)","jir_category":"","jir_hashtags":"#ASKAPharmaceuticalHoldings, #Earnings, #InterimResults","jir_key_figures":"Net sales: 355,626 million yen (YoY +1.1%)\nOperating income: 27,40 hundred million yen (YoY +3.5%)\nInterim net income: 20,06 hundred million yen (YoY -9.6%)","jir_meta_title":"ASKA Pharmaceutical Holdings Co.,Ltd. - Q2 Interim Financial Summary for FY March 2027 | Net Sales 35.56 billion yen, Net Income 2.006 billion yen","jir_meta_description":"Financial summary for ASKA Pharmaceutical Holdings Co.,Ltd. for the second quarter of FY ending March 2027: net sales 35.56 billion yen, operating income 2.74 billion yen, ordinary income 2.862 billion yen, interim net income 2.006 billion yen. No change to full-year forecast. Dividend outlook: 65 yen.","jir_og_title":"ASKA Pharmaceutical Holdings Co.,Ltd. Q2 Interim Financial Results","jir_og_description":"Financial summary for ASKA Pharmaceutical Holdings Co.,Ltd. for the second quarter of FY March 2027: net sales 35.56 billion yen, operating income 2.74 billion yen, interim net income 2.006 billion yen.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[]","ir_related_company":17164,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-141157","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n